Benefits of lowering cholesterol in chronic kidney disease.

摘要

The SHARP trial1 shows that a combination of simvastatin (20 mg) and ezetimibe (10 mg) is effective in the reduction of LDL cholesterol in patients with moderate-to-severe kidney disease. However, safety pertaining to the long-term use of simvastatin in these patients needs to be assessed in depth.In a large population-based cohort study in England and Wales,2 aimed at monitoring the unintended effectsof statins over a 6-year period (by contrast with the 4-9-year follow-up period in SHARP), the use of simvastatin was associated with an increased risk of renal failure even at doses of 10-20 mg/day.